Table II.
Discrimination performance of different diagnostic tests for peanut allergy in the principle study population (n = 42) and a subcohort of participants with equivocal tests (SPT or sIgE measurement, n = 24)
| Population | Diagnostic tests | Optimal cutoff∗ | AUC ROC (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | PLR (95% CI) | NLR (95% CI) | Odds ratio (95% CI) |
|---|---|---|---|---|---|---|---|---|
| Whole population (n = 42) | SPT (mm) | 8 | 0.73 (0.56-0.90) | 70 (50-85) | 75 (43-95) | 2.8 (1.0-7.7) | 0.08 (0.08-0.41) | 7 (1.5-32.1) |
| sIgE to peanut (kUA/L) | 3.8 | 0.93 (0.85-1.0) | 83 (65-94) | 92 (62-100) | 10 (1.5-66) | 0.18 (0.08-0.41) | 55 (5.7-527) | |
| sIgE to Ara h 2 (KUA/L) | 1.64 | 0.93 (0.86-1.0) | 77 (58-90) | 83 (52-98) | 4.6 (1.3-16) | 0.28 (0.14-0.56) | 16.4 (2.9-93) | |
| BAT, % CD63 | 7.8 | 0.94 (0.87-1.0) | 80 (61-92) | 89 (52-100) | 7.2 (1.1-46) | 0.22 (0.11-0.48) | 32 (3.3-308) | |
| MAT-AUC | 6.3 | 0.99 (0.96-1.0) | 97 (83-100) | 92 (62-100) | 11.6 (1.8-76) | 0.04 (0.01-0.25) | 319 (18.3-5556) | |
| Subgroup with equivocal SPT/sIgE results (n = 24) | SPT (mm) | 8 | 0.70 (0.48-0.90) | 75 (50-85) | 75 (43-95) | 3.0 (1.1-8.4) | 0.33 (0.12-0.94) | 9 (1.4-57) |
| Specific IgE (KUA/L) | 0.43 | 0.83 (0.65-1.0) | 100 (74-100) | 67 (62-100) | 3.0 (1.4-6.7) | 0 | ∞ | |
| Ara h 2 (KUA/L) | 0.72 | 0.83 (0.66-0.99) | 75 (43-95) | 83 (52-98) | 4.5 (1.2-16) | 0.30 (0.11-0.83) | 15 (2.0-111) | |
| BAT, % CD63 | 10.5 | 0.84 (0.67-1.0) | 83 (52-98) | 78 (40-97) | 3.8 (1.1-13) | 0.21 (0.06-0.80) | 17.5 (2.0-156) | |
| MAT-AUC | 6.3 | 0.97 (0.90-1.0) | 92 (62-100) | 92 (62-100) | 11.0 (1.7-72) | 0.09 (0.01-0.60) | 121 (6.7-2188) |
NLR, Negative likelihood ratio; PLR, positive likelihood ratio.
∗
Optimal cutoffs were determined by using the Youden index.